# Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia

Study · id `cardio:ct-nct05192941` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05192941](<https://clinicaltrials.gov/study/NCT05192941>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT05192941

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1770 participants.

## Technical summary

Registry record NCT05192941. Randomized; quadruple masking; primary purpose treatment. Start 2022-04-08 (actual); primary completion 2024-06-11 (actual). Results posted on 2026-04-14.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1770 participants (enrolled count; ClinicalTrials.gov record NCT05192941, source copy `cardio:ctgov-nct05192941-2026-04-14`, retrieved 2026-10-31)
- Started: 2022-04-08 (actual) (ClinicalTrials.gov record NCT05192941, source copy `cardio:ctgov-nct05192941-2026-04-14`, retrieved 2026-10-31)
- Primary completion: 2024-06-11 (actual) (ClinicalTrials.gov record NCT05192941, source copy `cardio:ctgov-nct05192941-2026-04-14`, retrieved 2026-10-31)
- Completion: 2025-03-19 (actual) (ClinicalTrials.gov record NCT05192941, source copy `cardio:ctgov-nct05192941-2026-04-14`, retrieved 2026-10-31)
- Results first posted: 2026-04-14 (ClinicalTrials.gov record NCT05192941, source copy `cardio:ctgov-nct05192941-2026-04-14`, retrieved 2026-10-31)
- Countries: Bulgaria; Czechia; Estonia; France; Germany; Latvia; Poland; Spain (ClinicalTrials.gov record NCT05192941, source copy `cardio:ctgov-nct05192941-2026-04-14`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05192941-2026-04-14`, retrieved 2026-10-31)

## The registry's words

- Brief title: Study of Efficacy, Safety, Tolerability and Quality of Life of Inclisiran (KJX839) vs Placebo, on Top of Ongoing Individually Optimized Lipid-lowering Therapy, in Participants With Hypercholesterolemia
- Acronym: V-DIFFERENCE
- Condition: Hypercholesterolemia
- Intervention (Drug): Inclisiran Sodium
- Intervention (Drug): Placebo
- Lead sponsor: Novartis Pharmaceuticals
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Inclisiran (`cardio:inclisiran`)
- Registry lists this organization as the lead sponsor: Novartis (`cardio:novartis`)

## Provenance

Content hash: 90a6763227fab968f7df273a5b5daac5c0c1161ffe049bc222ffc00b04c49200
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
